These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18847168)

  • 1. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
    Allez M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic approach in inflammatory bowel disease.
    Papa A; Mocci G; Scaldaferri F; Bonizzi M; Felice C; Andrisani G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():33-5. PubMed ID: 19530509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions.
    de Vries HS; van Oijen MG; van Hoven-van Loo KE; de Jong DJ
    J Clin Gastroenterol; 2009 Apr; 43(4):387-8. PubMed ID: 18987555
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 11. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM; Schmidt D; Karlén P
    Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract]   [Full Text] [Related]  

  • 14. A 61-year-old man with asymptomatic, bilateral lung masses.
    Rehman T; Ali J; Lopez FA
    J La State Med Soc; 2008; 160(6):309-14; quiz 349. PubMed ID: 19283977
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the association between the tumor necrosis factor-alpha inhibitor infliximab and complex regional pain syndrome type I?
    Paraskevas KI
    Paediatr Anaesth; 2008 Jul; 18(7):689-90. PubMed ID: 18331547
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
    Van Assche G
    Gut; 2011 Mar; 60(3):285-6. PubMed ID: 21193441
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.
    Mancini G; Erario L; Gianfreda R; Oliva A; Massetti AP; Mastroianni CM; Vullo V
    Clin Microbiol Infect; 2007 Oct; 13(10):1036-7. PubMed ID: 17711485
    [No Abstract]   [Full Text] [Related]  

  • 19. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents.
    Fiorino G; Danese S; Pariente B; Allez M
    Autoimmun Rev; 2014 Jan; 13(1):15-9. PubMed ID: 23777821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic options in the inflammatory bowel disease world.
    Noble A; Baldassano R; Mamula P
    Dig Liver Dis; 2008 Jan; 40(1):22-31. PubMed ID: 17988966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.